Literature DB >> 789047

Paediatric anaesthesia: pharmacological considerations.

D R Cook.   

Abstract

The young infant differs from the adult in his quantitative responses to many anaesthetic drugs and adjuncts. In the neonate, the larger extracellular fluid volume and blood volume, the smaller muscle mass and fat stores, and presumable greater blood flow to the central organs, not only influence the distribution of drugs to their active site but also secondary redistribution. The neonatal hepatic anzyme systems responsible for the metabolism of drugs are incompletely developed or absent. Glomerular filtration, important for drug excretion, is inefficient by adult standards. The neonate has increased toxicity and sensitivity to a variety of sedative-hypnotics, narcotics, and local anaesthetics. On the other hand, the infant requires more suxamethonium (succinylcholine) and ketamine on a weight basis that does the adult. The response of some infants to non-depolarising muscle relaxants resembles that of the myasthenic patients. The rate of uptake of alveolar levels of inhalation anesthetics is more rapid in infants and children than in adults. In addition, the neonate requires more anaesthetic than the adult for a given surgical stimulus. Biotransformation of inhalation anaesthetics is limited in neonates. Awareness of these pharmacological differences and their probable explanations allows one to provide rational, safer anaesthesia to infants.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 789047     DOI: 10.2165/00003495-197612030-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  35 in total

1.  RESPIRATORY SENSITIVITY OF THE NEWBORN INFANT TO MEPERIDINE AND MORPHINE.

Authors:  W L WAY; E C COSTLEY; E LEONGWAY
Journal:  Clin Pharmacol Ther       Date:  1965 Jul-Aug       Impact factor: 6.875

2.  Anaesthesia in new-born animals.

Authors:  J A WEATHERALL
Journal:  Br J Pharmacol Chemother       Date:  1960-09

3.  An ontogenetic study of phenobarbital-C-14 in cat brain.

Authors:  N S DOMEK; C F BARLOW; L J ROTH
Journal:  J Pharmacol Exp Ther       Date:  1960-11       Impact factor: 4.030

Review 4.  Developmental pharmacology.

Authors:  B L Mirkin
Journal:  Annu Rev Pharmacol       Date:  1970       Impact factor: 13.820

5.  Elimination kinetics of amobarbital in mothers and their newborn infants.

Authors:  B Krauer; G H Draffan; F M Williams; R A Clare; C T Dollery; D F Hawkins
Journal:  Clin Pharmacol Ther       Date:  1973 May-Jun       Impact factor: 6.875

6.  Pharmacokinetic principles in pediatric pharmacology.

Authors:  W J Jusko
Journal:  Pediatr Clin North Am       Date:  1972-02       Impact factor: 3.278

Review 7.  The metabolism of drugs employed in anesthesia. I.

Authors:  N M Greene
Journal:  Anesthesiology       Date:  1968 Jan-Feb       Impact factor: 7.892

Review 8.  Developmental pharmacology.

Authors:  F Sereni; N Principi
Journal:  Annu Rev Pharmacol       Date:  1968       Impact factor: 13.820

9.  Intravenous thiobarbiturate anesthesia for cesarean section.

Authors:  Y Kosaka; T Takahashi; L C Mark
Journal:  Anesthesiology       Date:  1969-12       Impact factor: 7.892

10.  Median effective doses (ED50) of halothane in adults and children.

Authors:  H F Nicodemus; C Nassiri-Rahimi; L Bachman; T C Smith
Journal:  Anesthesiology       Date:  1969-10       Impact factor: 7.892

View more
  2 in total

1.  Cardiopulmonary parameters during meperidine, promethazine, and chlorpromazine sedation for pediatric dentistry.

Authors:  M E Saravia; W R Currie; R L Campbell
Journal:  Anesth Prog       Date:  1987 May-Jun

2.  Population Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children.

Authors:  Christoph P Hornik; Daniel Gonzalez; John van den Anker; Andrew M Atz; Ram Yogev; Brenda B Poindexter; Kee Chong Ng; Paula Delmore; Barrie L Harper; Chiara Melloni; Andrew Lewandowski; Casey Gelber; Michael Cohen-Wolkowiez; Jan Hau Lee
Journal:  J Clin Pharmacol       Date:  2018-04-20       Impact factor: 2.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.